Michael A. Valek
41 IP cases indexed. Covers patent matters.
Cases Presided Over
41 cases indexed | Page 2 of 2
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
Samsung’s post‑grant review of Oura’s smart‑ring patent (U.S. 11,874,702) was denied. The Board held that none of the 17 claims were obvious over the cited prior art, affirming the patent’s validity.
Formycon AG v.Regeneron Pharmaceuticals, Inc.
The PTAB denied Formycon AG's IPR against Regeneron Pharmaceuticals, Inc., citing substantial overlap with parallel district court proceedings (MDL). The Board found that the interests of system efficiency were best served by denying institution.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB affirmed Guardant Health's U.S. Patent 11,149,306 covering cell‑free DNA tagging and counting, finding none of the 29 challenged claims unpatentable after Tempus AI's IPR challenge.
Samsung Electronics Co., Ltd. et al. v.Ouraring, Inc. et al.
The PTAB has instituted the IPR against Ouraring, Inc. et al., finding a reasonable likelihood of prevailing for Samsung Electronics Co., Ltd. et al. on multiple grounds of obviousness (103). The institution decision targets 17 claims related to smart rings and biometric monitoring technology.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
Samsung Electronics successfully petitioned to challenge Oura Health's patent (11868178) in a PGR proceeding, leading the PTAB to institute the case. The Board found Petitioner's arguments regarding prior art disclosures for battery and PCB placement sufficient to proceed to trial.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied Samsung's Post-Grant Review petition against Ouraing because the patent owner had statutorily disclaimed all 16 challenged claims.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
The PTAB denied a Post-Grant Review filed by Samsung against Oura Health's patent '701 because the Patent Owner had disclaimed all challenged claims.
Samsung Electronics Co., Ltd. et al. v.Oura Health Oy et al.
Samsung Electronics successfully petitioned to challenge Ouraring's patent (11874702) in a PGR proceeding, leading the PTAB to grant institution. The Board determined that the challenges based on prior art met the institutional threshold for trial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s '618 patent on grounds of enablement and obviousness regarding modified PH20 polypeptides. The PTAB adopted a functional claim construction requiring hyaluronidase activity for the claimed genus.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC challenged Halozyme, Inc.'s patent on hyaluronidase polypeptides under grounds of enablement and obviousness. The PTAB granted institution, finding the claims cover a vast genus that requires undue experimentation to fully enable.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB to invalidate Halozyme, Inc.'s claims covering a genus of modified PH20 polypeptides. The Board found that the broad scope of the claimed variants lacked adequate written description and enablement support in the original patent disclosure. This decision significantly challenges the breadth of the patented technology in hyaluronidase drug development.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.